Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type

INTRODUCTION: Factors affecting trastuzumab efficacy in advanced gastric cancer (GC) are largely unknown. Heterogeneity is a notable feature of HER2 in GC. Whether the heterogeneity influences trastuzumab efficacy is still unknown. RESULTS: The HER2(homogeneous) group and HER2(heterogeneous) group s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chen, Liu, Yalan, Jiang, Dongxian, Li, Qian, Ge, Xiaowen, Zhang, Ying, Huang, Jie, Su, Jieakesu, Ji, Yuan, Hou, Jun, Lu, Shaohua, Hou, Yingyong, Liu, Tianshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464860/
https://www.ncbi.nlm.nih.gov/pubmed/28388541
http://dx.doi.org/10.18632/oncotarget.16567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464860/
https://www.ncbi.nlm.nih.gov/pubmed/28388541
http://dx.doi.org/10.18632/oncotarget.16567

Ejemplares similares